BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19847889)

  • 1. SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia.
    Pizzatti L; Binato R; Cofre J; Gomes BE; Dobbin J; Haussmann ME; D'Azambuja D; Bouzas LF; Abdelhay E
    Genes Chromosomes Cancer; 2010 Feb; 49(2):107-18. PubMed ID: 19847889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.
    Corrêa S; Binato R; Du Rocher B; Castelo-Branco MT; Pizzatti L; Abdelhay E
    BMC Cancer; 2012 Jul; 12():303. PubMed ID: 22823957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression.
    Shen H; Chen Z; Ding X; Qi X; Cen J; Wang Y; Yao L; Chen Y
    J Cell Mol Med; 2014 Jun; 18(6):1004-17. PubMed ID: 24571310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL11A expression in acute phase chronic myeloid leukemia.
    Yin J; Zhang F; Tao H; Ma X; Su G; Xie X; Xu Z; Zheng Y; Liu H; He C; Mao ZJ; Wang Z; Chang W; Gale RP; Wu D; Yin B
    Leuk Res; 2016 Aug; 47():88-92. PubMed ID: 27285855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
    Li Z; Luo J
    Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z; Liu T; Zhang J
    Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells.
    Han Y; Wang Y; Xu Z; Li J; Yang J; Li Y; Shang Y; Luo J
    Oncol Rep; 2013 Aug; 30(2):1007-13. PubMed ID: 23733230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
    Mochmann LH; Bock J; Ortiz-Tánchez J; Schlee C; Bohne A; Neumann K; Hofmann WK; Thiel E; Baldus CD
    Oncogene; 2011 Apr; 30(17):2044-56. PubMed ID: 21242973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Pehlivan M; Caliskan C; Yuce Z; Sercan HO
    Tumour Biol; 2017 May; 39(5):1010428317701654. PubMed ID: 28468589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-catenin mutations are not observed in chronic myeloid leukemia.
    Sercan Z; Pehlivan M; Gokturk D; Sercan HO
    Tumori; 2009; 95(6):836-9. PubMed ID: 20210255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
    Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
    Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
    Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
    Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
    de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
    Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
    Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
    Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Eiring AM; Khorashad JS; Anderson DJ; Yu F; Redwine HM; Mason CC; Reynolds KR; Clair PM; Gantz KC; Zhang TY; Pomicter AD; Kraft IL; Bowler AD; Johnson K; Partlin MM; O'Hare T; Deininger MW
    Leukemia; 2015 Dec; 29(12):2328-37. PubMed ID: 26202934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.